Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

被引：1
|
作者：
Oarbeascoa, Gillen [1 ]
Redondo, Sara [2 ]
Jose Moran-Jimenez, Maria [3 ]
Domingo, Amalia [1 ]
Munoz-Linares, Cristina [2 ]
Isabel Moreno-Carralero, Maria [4 ]
Maria Bellon, Jose [5 ]
del Campo Rincon, Juan Francisco [2 ]
Luis Diez-Martin, Jose [1 ,5 ,6 ]
Font, Patricia [1 ,5 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Hematol Dept, Madrid, Spain
[2] Hosp Univ Henares, Hematol Dept, Madrid, Spain
[3] Hosp 12 Octubre I 12, Inst Invest Sanitaria, Madrid, Spain
[4] Hosp 12 Octubre Imas12, Inst Invest Sanitaria, Madrid, Spain
[5] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[6] Univ Complutense Madrid, Dept Med, Madrid, Spain
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-116992
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3085
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Luspatercept: a candidate to dethrone erythropoietin in first line in low-risk myelodysplastic syndromes?
    Robert-Van Houtteghem, Tristan
    HEMATOLOGIE, 2023, 29 (05): : 269 - 271
  • [42] Efficacy of growth factors compared to chemotherapy in low-risk myelodysplastic syndromes.
    Golshayan, A
    Fu, AZ
    Kattan, MW
    Brown, S
    Maciejewski, JP
    Sekeres, MA
    BLOOD, 2005, 106 (11) : 713A - 714A
  • [43] Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes
    Golshayan, Ali-Reza
    Jin, Tao
    Maciejewski, Jaroslaw
    Fu, Alex Z.
    Bershadsky, Boris
    Kattan, Michael W.
    Kalaycio, Matt E.
    Sekeres, Mikkael A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (02) : 125 - 132
  • [44] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.
    Sekeres, MA
    Fu, AZ
    Maciejewski, JP
    Golshayan, AR
    Kalaycio, M
    Kattan, MW
    BLOOD, 2005, 106 (11) : 711A - 711A
  • [45] BIOSIMILAR EPOETIN IN ELDERLY PATIENTS WITH LOW-RISK/INTERMEDIATE 1 MYELODYSPLASTIC SYNDROMES IMPROVES ANEMIA, QUALITY OF LIFE AND BRAIN FUNCTION
    Castelli, R.
    Deliliers, G. Lambertenghi
    Colombo, R.
    Gallipoli, P.
    Pantaleo, G.
    HAEMATOLOGICA, 2014, 99 : 616 - 616
  • [46] Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia
    Latour, Chloe
    Wlodarczyk, Myriam F.
    Jung, Grace
    Gineste, Aurelie
    Blanchard, Nicolas
    Ganz, Tomas
    Roth, Marie-Paule
    Coppin, Helene
    Kautz, Leon
    HAEMATOLOGICA, 2017, 102 (01) : 60 - 68
  • [47] ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES
    Cerchione, C.
    Martinelli, G.
    Soriente, I.
    D'Arco, A. M.
    Danise, P.
    Cerciello, G.
    Di Battista, V.
    Cangini, D.
    Giannini, M. B.
    Pane, F.
    Alfinito, F.
    HAEMATOLOGICA, 2019, 104 : 147 - 148
  • [48] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Angel F. Remacha
    Beatriz Arrizabalaga
    Consuelo Del Cañizo
    Guillermo Sanz
    Ana Villegas
    Annals of Hematology, 2010, 89 : 147 - 154
  • [49] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Remacha, Angel F.
    Arrizabalaga, Beatriz
    Del Canizo, Consuelo
    Sanz, Guillermo
    Villegas, Ana
    ANNALS OF HEMATOLOGY, 2010, 89 (02) : 147 - 154
  • [50] Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes
    Patel, Bhumika
    Saygin, Caner
    Przychodzen, Bartlomiej P.
    Kuzmanovic, Teodora
    Hirsch, Cassandra M.
    Clemente, Michael J.
    Thota, Swapna
    Nazha, Aziz
    Mikkael, Sekeres A.
    Maciejewski, Jaroslaw P.
    Carraway, Hetty E.
    BLOOD, 2016, 128 (22)
12345